Trials / Completed
CompletedNCT00411424
Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Initial Efficacy of ASK8007 in Comparison With Placebo in Patients With Active Rheumatoid Arthritis - a Randomized, Double Blind, Placebo-controlled, Combined Single Dose Escalation and Multiple Dose Study
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety and tolerability of the new medication ASK8007, and to study whether it has a beneficial effect on joint inflammation in patients with rheumatoid arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASK8007 | IV |
| DRUG | Placebo | IV |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2006-12-14
- Last updated
- 2013-03-21
Locations
10 sites across 6 countries: Belgium, Hungary, Ireland, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00411424. Inclusion in this directory is not an endorsement.